Market Cap ₹1155 Cr.
Stock P/E 0.0
P/B 14.1
Current Price ₹7840
Book Value ₹ 557.1
Face Value 10
52W High ₹8747
Dividend Yield 0.03%
52W Low ₹ 1711.3
Remus Pharmaceuticals Ltd is a cutting-edge pharmaceutical company that specializes in the research, development, and production of innovative medical solutions. With a strong commitment to improving global healthcare, Remus Pharmaceuticals focuses on addressing unmet medical needs and enhancing patient outcomes. The company employs a multidisciplinary approach, leveraging advanced technologies and scientific expertise to discover and develop novel therapeutics. Remus Pharmaceuticals has a diverse portfolio that spans various therapeutic areas, including oncology, neurology, cardiovascular diseases, and rare genetic disorders. The company's dedicated team of researchers, scientists, and healthcare professionals collaborate closely to drive innovation and translate scientific discoveries into impactful treatments. With a strong emphasis on quality and safety, Remus Pharmaceuticals adheres to stringent regulatory standards and actively engages in clinical trials to validate the efficacy and safety of their products. By combining scientific excellence, ethical practices, and a patient-centric approach, Remus Pharmaceuticals aims to revolutionize healthcare by delivering transformative therapies to patients worldwide.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|
| Net Sales | 12 | 18 | 25 | 45 | |
| Other Income | 1 | 1 | 1 | 2 | |
| Total Income | 13 | 19 | 25 | 47 | |
| Total Expenditure | 12 | 18 | 21 | 34 | |
| Operating Profit | 1 | 2 | 5 | 12 | |
| Interest | 0 | 0 | 0 | 0 | |
| Depreciation | 0 | 0 | 0 | 0 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 1 | 1 | 5 | 11 | |
| Provision for Tax | 0 | 0 | 1 | 3 | |
| Profit After Tax | 1 | 1 | 3 | 9 | |
| Adjustments | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 1 | 1 | 3 | 9 | |
| Adjusted Earnings Per Share | 8.1 | 10.3 | 34.3 | 78.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 80% | 55% | 0% | 0% |
| Operating Profit CAGR | 140% | 129% | 0% | 0% |
| PAT CAGR | 200% | 108% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 66% | 59% | 55% | 55% |
| ROCE Average | 69% | 70% | 65% | 65% |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|
| Shareholder's Funds | 2 | 3 | 7 | 19 |
| Minority's Interest | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 7 |
| Other Non-Current Liabilities | 0 | 0 | -0 | 0 |
| Total Current Liabilities | 3 | 8 | 9 | 8 |
| Total Liabilities | 5 | 11 | 16 | 35 |
| Fixed Assets | 1 | 0 | 0 | 3 |
| Other Non-Current Assets | 0 | 3 | 8 | 21 |
| Total Current Assets | 5 | 8 | 8 | 11 |
| Total Assets | 5 | 11 | 16 | 35 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 1 | 1 | 1 |
| Cash Flow from Operating Activities | 1 | 3 | 5 | 5 |
| Cash Flow from Investing Activities | -1 | -3 | -5 | -15 |
| Cash Flow from Financing Activities | 0 | -0 | -0 | 12 |
| Net Cash Inflow / Outflow | 1 | -0 | 0 | 2 |
| Closing Cash & Cash Equivalent | 1 | 1 | 1 | 3 |
| # | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 8.12 | 10.26 | 34.34 | 78.37 |
| CEPS(Rs) | 9.18 | 12.01 | 35.89 | 82.77 |
| DPS(Rs) | 0 | 0 | 0 | 2 |
| Book NAV/Share(Rs) | 20.2 | 30.46 | 65.78 | 176.36 |
| Core EBITDA Margin(%) | 3.29 | 4.14 | 16.73 | 23.42 |
| EBIT Margin(%) | 9.54 | 7.56 | 19.02 | 25.87 |
| Pre Tax Margin(%) | 9.18 | 7.37 | 18.66 | 25.35 |
| PAT Margin (%) | 6.81 | 5.57 | 13.89 | 18.88 |
| Cash Profit Margin (%) | 7.7 | 6.52 | 14.52 | 19.94 |
| ROA(%) | 15.38 | 12.61 | 25.62 | 33.77 |
| ROE(%) | 40.17 | 40.49 | 71.37 | 66.14 |
| ROCE(%) | 47.76 | 48.84 | 93.13 | 68.82 |
| Receivable days | 49.83 | 51.83 | 48.13 | 31.46 |
| Inventory Days | 13.37 | 15.73 | 20.23 | 7.6 |
| Payable days | 67.87 | 102.7 | 146.27 | 69.84 |
| PER(x) | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | -0.07 | -0.03 | 0 | 0.13 |
| EV/Core EBITDA(x) | -0.67 | -0.35 | 0.01 | 0.49 |
| Net Sales Growth(%) | 0 | 54.53 | 34.13 | 82.27 |
| EBIT Growth(%) | 0 | 22.59 | 237.4 | 147.76 |
| PAT Growth(%) | 0 | 26.39 | 234.77 | 147.6 |
| EPS Growth(%) | 0 | 26.39 | 234.77 | 128.2 |
| Debt/Equity(x) | 0.18 | 0.09 | 0.03 | 0.42 |
| Current Ratio(x) | 1.63 | 0.98 | 0.84 | 1.39 |
| Quick Ratio(x) | 1.48 | 0.83 | 0.66 | 1.35 |
| Interest Cover(x) | 26.74 | 39.69 | 53.91 | 50.09 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 |
| # | Sep 2023 | Mar 2024 |
|---|---|---|
| Promoter | 69.61 | 70.6 |
| FII | 2.38 | 3.25 |
| DII | 0.71 | 0.67 |
| Public | 27.3 | 25.49 |
| Others | 0 | 0 |
| Total | 100 | 100 |
| # | Sep 2023 | Mar 2024 |
|---|---|---|
| Promoter | 0.1 | 0.1 |
| FII | 0 | 0 |
| DII | 0 | 0 |
| Public | 0.04 | 0.04 |
| Others | 0 | 0 |
| Total | 0.15 | 0.15 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Sell or Purchase Share (Tentative Price)
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
